AbCellera Biologics (ABCL) Receivables - Other (2020 - 2021)
AbCellera Biologics' (ABCL) quarterly Receivables - Other came in at $62.1 million in Q2 2021, down 67.84% on a QoQ basis from $193.1 million in Q1 2021.
AbCellera Biologics (ABCL) Receivables - Other (2020 - 2021) Analysis & Trends
AbCellera Biologics (ABCL) has 2 years of Receivables - Other data on file, last reported at $62.1 million in Q2 2021.
- Quarterly Receivables - Other changed N/A year-over-year to $62.1 million in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $62.1 million (changed N/A YoY) and the FY2020 annual result came in at $212.3 million, changed N/A from the prior year.
- Receivables - Other fell to $62.1 million in Q2 2021, from $193.1 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $212.3 million in Q4 2020 to a low of $62.1 million in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | AbCellera Biologics | 3.49 Bn | 3.49 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 62.09 Mn |
| Jun 30, 2021 | 62.09 Mn |
| Mar 31, 2021 | 193.07 Mn |
| Mar 31, 2021 | 193.07 Mn |
| Dec 31, 2020 | 212.34 Mn |
| Dec 31, 2020 | 212.34 Mn |